DPF2 Activators
DPF2 Activators encompass a range of chemical compounds that indirectly bolster the functional activity of DPF2 through modulation of various signaling pathways and chromatin remodeling processes. Histone deacetylase inhibitors such as SAHA (Vorinostat) and Trichostatin A enhance chromatin accessibility, which could augment the binding of DPF2 to its target DNA sequences, thereby potentiating its role in gene regulation. DNA methyltransferase inhibitors like 5-Aza-2'-deoxycytidine contribute to a similar effect by inducing gene hypomethylation, potentially making promoter regions more amenable to DPF2-mediated transcription. The ubiquitin-proteasome pathway modulator, (R)-Thalidomide, and the proteasome inhibitor MG132 could indirectly increase DPF2 activity by influencing the turnover of proteins that regulate DPF2's functional stability. Bromodomain inhibitor JQ1 and WDR5 interaction inhibitor OICR-9429 could further enhance DPF2 activity by preventing competitive binding at chromatin sites or affecting the assembly of histone modification complexes that interact with DPF2, respectively.
Additionally, second messenger systems are implicated in the regulation of DPF2 activity through the actions of Forskolin and PMA, which activate adenylyl cyclase and protein kinase C, leading to downstream phosphorylation events that may modulate DPF2's transcriptional activity. Lithium chloride, by inhibiting GSK-3 within the Wnt signaling pathway, could also indirectly influence the gene expression patterns regulated by DPF2. Retinoic acid, by affecting gene expression through its receptor interaction with chromatin remodeling complexes, might enhance DPF2's regulatory capacity. Lastly, Epigallocatechin gallate, a polyphenol that inhibits both DNA methyltransferases and histone deacetylases, could facilitate a more open chromatin state, potentially increasing the transcriptional activity of DPF2. Together, these activators work through distinct but convergent pathways to enhance the regulatory functions of DPF2, facilitating its role in chromatin remodeling and gene expression without direct activation or upregulation of its expression.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
SAHA is a histone deacetylase inhibitor. By preventing deacetylation, it can lead to a more open chromatin structure, potentially enhancing the accessibility of DPF2 to its target DNA sequences and thus increasing its functional activity. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, like SAHA, inhibits histone deacetylases. This promotes histone acetylation, which could indirectly increase DPF2 activity by facilitating transcriptional programs where DPF2 is a co-activator. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
This compound is a DNA methyltransferase inhibitor. It could lead to the hypomethylation of genes, potentially increasing the expression of genes regulated by DPF2 by making their promoters more accessible to the transcription machinery. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
As a modulator of the ubiquitin-proteasome pathway, (R)-Thalidomide could indirectly affect DPF2 by altering the levels of proteins that interact with or regulate DPF2, thereby modulating its activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that could prevent the degradation of DPF2 or its co-regulatory proteins, potentially leading to increased DPF2 activity due to higher protein stability. | ||||||
Lithium | 7439-93-2 | sc-252954 | 50 g | $214.00 | ||
Lithium chloride inhibits GSK-3, which may lead to altered phosphorylation states of proteins within the Wnt signaling pathway. This could indirectly enhance DPF2 activity if it influences gene expression patterns DPF2 regulates. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing cAMP levels, which could enhance protein kinase A (PKA) activity. PKA may phosphorylate factors that modulate the transcriptional activity of DPF2 or its associated complexes. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which could phosphorylate substrates that influence chromatin remodeling and thus potentially enhance the functional activity of DPF2 in gene regulation. | ||||||
Retinoic Acid, all trans | 302-79-4 | sc-200898 sc-200898A sc-200898B sc-200898C | 500 mg 5 g 10 g 100 g | $66.00 $325.00 $587.00 $1018.00 | 28 | |
Retinoic acid influences gene expression through its receptor, which may interact with chromatin remodeling complexes including those associated with DPF2, potentially enhancing the regulatory role of DPF2. | ||||||